25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

BVS (Bioventus) Stock Analysis
Buy, Hold or Sell?

Let's analyze Bioventus together

I guess you are interested in Bioventus Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • 📊 Fundamental Analysis (FA) – Bioventus’s Financial Insights
  • 📈 Technical Analysis (TA) – Bioventus’s Price Targets

I'm going to help you getting a better view of Bioventus Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Bioventus Inc

I send you an email if I find something interesting about Bioventus Inc.

1. Quick Overview

1.1. Quick analysis of Bioventus (30 sec.)










1.2. What can you expect buying and holding a share of Bioventus? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
38.5%

What is your share worth?

Current worth
$2.80
Expected worth in 1 year
$2.31
How sure are you?
34.6%

+ What do you gain per year?

Total Gains per Share
$-0.48
Return On Investment
-6.9%

For what price can you sell your share?

Current Price per Share
$6.97
Expected price per share
$6.3341 - $10.13
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Bioventus (5 min.)




Live pricePrice per Share (EOD)
$6.97
Intrinsic Value Per Share
$4.70 - $5.61
Total Value Per Share
$7.50 - $8.40

2.2. Growth of Bioventus (5 min.)




Is Bioventus growing?

Current yearPrevious yearGrowGrow %
How rich?$185.4m$224.5m-$37.8m-20.3%

How much money is Bioventus making?

Current yearPrevious yearGrowGrow %
Making money-$7.9m-$5.4m-$2.4m-31.5%
Net Profit Margin-5.4%-4.2%--

How much money comes from the company's main activities?

2.3. Financial Health of Bioventus (5 min.)




2.4. Comparing to competitors in the Medical Devices industry (5 min.)




  Industry Rankings (Medical Devices)  


Richest
#98 / 292

Most Revenue
#58 / 292

Most Profit
#229 / 292

Most Efficient
#137 / 292
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Bioventus?

Welcome investor! Bioventus's management wants to use your money to grow the business. In return you get a share of Bioventus.

First you should know what it really means to hold a share of Bioventus. And how you can make/lose money.

Speculation

The Price per Share of Bioventus is $6.97. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Bioventus.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Bioventus, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $2.80. Based on the TTM, the Book Value Change Per Share is $-0.12 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.09 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Bioventus.

How much money are you going to get?

 MRQTTMYOY3Y5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.04-0.6%-0.12-1.7%-0.08-1.2%-0.42-6.1%-0.25-3.6%-0.19-2.7%
Usd Book Value Change Per Share0.000.0%-0.12-1.7%-0.09-1.2%-0.42-6.1%0.030.5%0.111.5%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.020.3%0.020.3%
Usd Total Gains Per Share0.000.0%-0.12-1.7%-0.09-1.2%-0.42-6.1%0.050.7%0.131.9%
Usd Price Per Share9.15-9.34-4.17-5.96-7.36-5.66-
Price to Earnings Ratio-57.56--304.81--13.43--101.90--109.19--83.99-
Price-to-Total Gains Ratio-4,857.38--1,448.38--54.56--523.51--446.70--446.70-
Price to Book Ratio3.27-3.32-1.24-1.76-1.94-1.49-
Price-to-Total Gains Ratio-4,857.38--1,448.38--54.56--523.51--446.70--446.70-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share6.97
Number of shares143
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.02
Usd Book Value Change Per Share-0.120.03
Usd Total Gains Per Share-0.120.05
Gains per Quarter (143 shares)-17.217.45
Gains per Year (143 shares)-68.8629.82
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-69-79111920
20-138-148223850
30-207-217335680
40-275-2864475110
50-344-3555594140
60-413-42466113170
70-482-49377132200
80-551-56288151230
90-620-63199169260
100-689-700110188290

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%1.011.00.08.3%4.016.00.020.0%7.019.00.026.9%7.020.00.025.9%
Book Value Change Per Share0.04.00.00.0%0.012.00.00.0%4.015.01.020.0%5.017.04.019.2%5.017.05.018.5%
Dividend per Share0.00.04.00.0%0.00.012.00.0%7.00.013.035.0%10.00.016.038.5%10.00.017.037.0%
Total Gains per Share0.04.00.00.0%0.012.00.00.0%6.014.00.030.0%9.015.02.034.6%9.015.03.033.3%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Bioventus Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-3Y+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.002-0.120+6291%-0.086+4486%-0.423+22329%0.033-106%0.108-102%
Book Value Per Share--2.7952.814-1%3.384-17%3.925-29%3.980-30%3.660-24%
Current Ratio--1.4271.371+4%1.517-6%1.363+5%1.515-6%1.330+7%
Debt To Asset Ratio--0.7320.749-2%0.724+1%0.723+1%0.695+5%0.684+7%
Debt To Equity Ratio--3.4153.749-9%3.338+2%3.295+4%2.936+16%2.694+27%
Dividend Per Share----0%-0%-0%0.019-100%0.023-100%
Enterprise Value--124039040.00095962840.000+29%-282749096.000+328%-234869335.333+289%-1701219.765+101%-1701219.765+101%
Eps---0.040-0.119+200%-0.082+105%-0.423+965%-0.251+533%-0.190+378%
Ev To Ebitda Ratio--1.9432.706-28%-4.134+313%2.314-16%4.905-60%4.905-60%
Ev To Sales Ratio--0.2500.178+41%-0.543+317%-0.464+286%0.070+257%0.070+257%
Free Cash Flow Per Share---0.3040.090-437%0.010-3026%0.033-1030%0.038-908%0.059-618%
Free Cash Flow To Equity Per Share---0.289-0.096-67%-0.209-28%-0.002-99%0.171-269%0.186-255%
Gross Profit Margin--1.0001.0000%1.158-14%1.066-6%1.522-34%1.401-29%
Intrinsic Value_10Y_max--5.609----------
Intrinsic Value_10Y_min--4.703----------
Intrinsic Value_1Y_max--0.193----------
Intrinsic Value_1Y_min--0.190----------
Intrinsic Value_3Y_max--0.862----------
Intrinsic Value_3Y_min--0.817----------
Intrinsic Value_5Y_max--1.869----------
Intrinsic Value_5Y_min--1.711----------
Market Cap462512472.000-31%607172040.000619614090.000-2%276379404.000+120%395435998.000+54%488192863.200+24%375532971.692+62%
Net Profit Margin---0.021-0.054+153%-0.042+97%-0.225+956%-0.126+490%-0.093+339%
Operating Margin--0.033-0.017+152%0.029+14%-0.152+560%-0.083+352%-0.045+236%
Operating Ratio--0.9611.010-5%0.970-1%1.097-12%1.055-9%1.024-6%
Pb Ratio2.494-31%3.2743.322-1%1.239+164%1.762+86%1.937+69%1.490+120%
Pe Ratio-43.848+24%-57.563-304.807+430%-13.435-77%-101.900+77%-109.193+90%-83.995+46%
Price Per Share6.970-31%9.1509.338-2%4.165+120%5.959+54%7.357+24%5.659+62%
Price To Free Cash Flow Ratio-5.736+24%-7.5316.855-210%-1.288-83%8.688-187%7.531-200%5.793-230%
Price To Total Gains Ratio-3700.100+24%-4857.376-1448.377-70%-54.561-99%-523.510-89%-446.703-91%-446.703-91%
Quick Ratio--0.8060.780+3%0.871-7%0.792+2%1.030-22%1.066-24%
Return On Assets---0.004-0.010+166%-0.007+75%-0.028+623%-0.015+290%-0.011+182%
Return On Equity---0.018-0.053+195%-0.031+73%-0.125+604%-0.068+280%-0.049+176%
Total Gains Per Share---0.002-0.120+6291%-0.086+4486%-0.423+22329%0.052-104%0.131-101%
Usd Book Value--185479000.000186744500.000-1%224586750.000-17%260446250.000-29%264124750.000-30%242888884.615-24%
Usd Book Value Change Per Share---0.002-0.120+6291%-0.086+4486%-0.423+22329%0.033-106%0.108-102%
Usd Book Value Per Share--2.7952.814-1%3.384-17%3.925-29%3.980-30%3.660-24%
Usd Dividend Per Share----0%-0%-0%0.019-100%0.023-100%
Usd Enterprise Value--124039040.00095962840.000+29%-282749096.000+328%-234869335.333+289%-1701219.765+101%-1701219.765+101%
Usd Eps---0.040-0.119+200%-0.082+105%-0.423+965%-0.251+533%-0.190+378%
Usd Free Cash Flow---20157000.0005982000.000-437%689000.000-3026%2167833.333-1030%2495650.000-908%3892307.692-618%
Usd Free Cash Flow Per Share---0.3040.090-437%0.010-3026%0.033-1030%0.038-908%0.059-618%
Usd Free Cash Flow To Equity Per Share---0.289-0.096-67%-0.209-28%-0.002-99%0.171-269%0.186-255%
Usd Market Cap462512472.000-31%607172040.000619614090.000-2%276379404.000+120%395435998.000+54%488192863.200+24%375532971.692+62%
Usd Price Per Share6.970-31%9.1509.338-2%4.165+120%5.959+54%7.357+24%5.659+62%
Usd Profit---2637000.000-7902250.000+200%-5412500.000+105%-28319666.667+974%-16313550.000+519%-12205000.000+363%
Usd Revenue--123876000.000141924750.000-13%130685750.000-5%133694000.000-7%119751600.000+3%110739230.769+12%
Usd Total Gains Per Share---0.002-0.120+6291%-0.086+4486%-0.423+22329%0.052-104%0.131-101%
 EOD+3 -5MRQTTM+22 -15YOY+21 -173Y+21 -175Y+16 -2410Y+17 -23

3.3 Fundamental Score

Let's check the fundamental score of Bioventus Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-43.848
Price to Book Ratio (EOD)Between0-12.494
Net Profit Margin (MRQ)Greater than0-0.021
Operating Margin (MRQ)Greater than00.033
Quick Ratio (MRQ)Greater than10.806
Current Ratio (MRQ)Greater than11.427
Debt to Asset Ratio (MRQ)Less than10.732
Debt to Equity Ratio (MRQ)Less than13.415
Return on Equity (MRQ)Greater than0.15-0.018
Return on Assets (MRQ)Greater than0.05-0.004
Total3/10 (30.0%)

3.4 Technical Score

Let's check the technical score of Bioventus Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5052.374
Ma 20Greater thanMa 506.785
Ma 50Greater thanMa 1006.731
Ma 100Greater thanMa 2007.892
OpenGreater thanClose7.320
Total3/5 (60.0%)

4. In-depth Analysis

4.1 About Bioventus Inc

Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally. The company's product portfolio includes pain treatments, which comprise of various intra-articular and hyaluronic acid injections; peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis; and Stimrouter to treat chronic peripheral pain. It also offers precision bone resection for patients with degenerative spine conditions and spinal deformities, as well as enables precision ultrasonic neuro and general surgery to address brain tumors and pathologies of the liver and other organs; and bone graft substitutes, including various products that facilitate optimal bone fusion. In addition, the company provides nexus, an ultrasonic surgical system; BoneScalpel, a surgical solution enabling precise cuts in hard tissue; SonaStar system, a precise ablation and removal of soft tissue; SonaStar Elite handpiece and accessories; SonicOne, an ultrasonic cleansing and debridement system; Osteoamp, an allograft-derived bone graft for orthopedic, neurosurgical, and reconstructive bone grafting procedures; Signafuse bone graft; Purebone, a natural osteoconductive scaffold; and Reficio demineralized bone matrix. The company's restorative therapies include minimally invasive fracture treatments and rehabilitation products. Its products also include Exogen, an ultrasound bone stimulation system; and Talisman pulse generator and receiver for peripheral nerve stimulation. Bioventus Inc. was founded in 2011 and is headquartered in Durham, North Carolina.

Fundamental data was last updated by Penke on 2025-07-10 23:00:06.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is just able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is unable to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is fair priced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is cheap.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Bioventus earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Bioventus to the Medical Devices industry mean.
  • A Net Profit Margin of -2.1% means that $-0.02 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Bioventus Inc:

  • The MRQ is -2.1%. The company is making a loss. -1
  • The TTM is -5.4%. The company is making a loss. -1
Trends
Current periodCompared to+/- 
MRQ-2.1%TTM-5.4%+3.3%
TTM-5.4%YOY-4.2%-1.2%
TTM-5.4%5Y-12.6%+7.2%
5Y-12.6%10Y-9.3%-3.2%
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.1%-7.9%+5.8%
TTM-5.4%-10.4%+5.0%
YOY-4.2%-13.5%+9.3%
3Y-22.5%-14.5%-8.0%
5Y-12.6%-10.7%-1.9%
10Y-9.3%-11.1%+1.8%
4.3.1.2. Return on Assets

Shows how efficient Bioventus is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Bioventus to the Medical Devices industry mean.
  • -0.4% Return on Assets means that Bioventus generated $0.00 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Bioventus Inc:

  • The MRQ is -0.4%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -1.0%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-0.4%TTM-1.0%+0.6%
TTM-1.0%YOY-0.7%-0.3%
TTM-1.0%5Y-1.5%+0.5%
5Y-1.5%10Y-1.1%-0.4%
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
MRQ-0.4%-2.1%+1.7%
TTM-1.0%-2.4%+1.4%
YOY-0.7%-3.5%+2.8%
3Y-2.8%-2.9%+0.1%
5Y-1.5%-2.7%+1.2%
10Y-1.1%-2.4%+1.3%
4.3.1.3. Return on Equity

Shows how efficient Bioventus is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Bioventus to the Medical Devices industry mean.
  • -1.8% Return on Equity means Bioventus generated $-0.02 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Bioventus Inc:

  • The MRQ is -1.8%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -5.3%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-1.8%TTM-5.3%+3.5%
TTM-5.3%YOY-3.1%-2.2%
TTM-5.3%5Y-6.8%+1.5%
5Y-6.8%10Y-4.9%-1.9%
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
MRQ-1.8%-2.0%+0.2%
TTM-5.3%-3.2%-2.1%
YOY-3.1%-3.9%+0.8%
3Y-12.5%-4.0%-8.5%
5Y-6.8%-4.4%-2.4%
10Y-4.9%-6.3%+1.4%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Bioventus Inc.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Bioventus is operating .

  • Measures how much profit Bioventus makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Bioventus to the Medical Devices industry mean.
  • An Operating Margin of 3.3% means the company generated $0.03  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Bioventus Inc:

  • The MRQ is 3.3%. The company is operating less efficient.
  • The TTM is -1.7%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ3.3%TTM-1.7%+5.0%
TTM-1.7%YOY2.9%-4.6%
TTM-1.7%5Y-8.3%+6.6%
5Y-8.3%10Y-4.5%-3.8%
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
MRQ3.3%-12.1%+15.4%
TTM-1.7%-13.7%+12.0%
YOY2.9%-11.9%+14.8%
3Y-15.2%-11.3%-3.9%
5Y-8.3%-10.3%+2.0%
10Y-4.5%-12.2%+7.7%
4.3.2.2. Operating Ratio

Measures how efficient Bioventus is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Medical Devices industry mean).
  • An Operation Ratio of 0.96 means that the operating costs are $0.96 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Bioventus Inc:

  • The MRQ is 0.961. The company is less efficient in keeping operating costs low.
  • The TTM is 1.010. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ0.961TTM1.010-0.049
TTM1.010YOY0.970+0.040
TTM1.0105Y1.055-0.045
5Y1.05510Y1.024+0.031
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
MRQ0.9611.397-0.436
TTM1.0101.389-0.379
YOY0.9701.295-0.325
3Y1.0971.342-0.245
5Y1.0551.375-0.320
10Y1.0241.328-0.304
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Bioventus Inc.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Bioventus is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Medical Devices industry mean).
  • A Current Ratio of 1.43 means the company has $1.43 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Bioventus Inc:

  • The MRQ is 1.427. The company is just able to pay all its short-term debts.
  • The TTM is 1.371. The company is just able to pay all its short-term debts.
Trends
Current periodCompared to+/- 
MRQ1.427TTM1.371+0.056
TTM1.371YOY1.517-0.146
TTM1.3715Y1.515-0.144
5Y1.51510Y1.330+0.185
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
MRQ1.4272.473-1.046
TTM1.3712.589-1.218
YOY1.5172.630-1.113
3Y1.3632.884-1.521
5Y1.5153.528-2.013
10Y1.3303.291-1.961
4.4.3.2. Quick Ratio

Measures if Bioventus is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Bioventus to the Medical Devices industry mean.
  • A Quick Ratio of 0.81 means the company can pay off $0.81 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Bioventus Inc:

  • The MRQ is 0.806. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.780. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.806TTM0.780+0.026
TTM0.780YOY0.871-0.090
TTM0.7805Y1.030-0.250
5Y1.03010Y1.066-0.036
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
MRQ0.8061.079-0.273
TTM0.7801.398-0.618
YOY0.8711.638-0.767
3Y0.7921.815-1.023
5Y1.0302.139-1.109
10Y1.0662.338-1.272
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Bioventus Inc.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Bioventus assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Bioventus to Medical Devices industry mean.
  • A Debt to Asset Ratio of 0.73 means that Bioventus assets are financed with 73.2% credit (debt) and the remaining percentage (100% - 73.2%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Bioventus Inc:

  • The MRQ is 0.732. The company is able to pay all its debts by selling its assets. +1
  • The TTM is 0.749. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ0.732TTM0.749-0.017
TTM0.749YOY0.724+0.025
TTM0.7495Y0.695+0.054
5Y0.69510Y0.684+0.011
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
MRQ0.7320.409+0.323
TTM0.7490.419+0.330
YOY0.7240.401+0.323
3Y0.7230.391+0.332
5Y0.6950.424+0.271
10Y0.6840.457+0.227
4.5.4.2. Debt to Equity Ratio

Measures if Bioventus is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Bioventus to the Medical Devices industry mean.
  • A Debt to Equity ratio of 341.5% means that company has $3.42 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Bioventus Inc:

  • The MRQ is 3.415. The company is unable to pay all its debts with equity. -1
  • The TTM is 3.749. The company is unable to pay all its debts with equity. -1
Trends
Current periodCompared to+/- 
MRQ3.415TTM3.749-0.333
TTM3.749YOY3.338+0.410
TTM3.7495Y2.936+0.812
5Y2.93610Y2.694+0.242
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
MRQ3.4150.608+2.807
TTM3.7490.648+3.101
YOY3.3380.623+2.715
3Y3.2950.644+2.651
5Y2.9360.683+2.253
10Y2.6940.757+1.937
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Bioventus generates.

  • Above 15 is considered overpriced but always compare Bioventus to the Medical Devices industry mean.
  • A PE ratio of -57.56 means the investor is paying $-57.56 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Bioventus Inc:

  • The EOD is -43.848. Based on the earnings, the company is expensive. -2
  • The MRQ is -57.563. Based on the earnings, the company is expensive. -2
  • The TTM is -304.807. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-43.848MRQ-57.563+13.714
MRQ-57.563TTM-304.807+247.244
TTM-304.807YOY-13.435-291.372
TTM-304.8075Y-109.193-195.614
5Y-109.19310Y-83.995-25.198
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
EOD-43.848-1.295-42.553
MRQ-57.563-1.518-56.045
TTM-304.807-1.257-303.550
YOY-13.435-2.406-11.029
3Y-101.900-1.572-100.328
5Y-109.193-1.938-107.255
10Y-83.995-1.705-82.290
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Bioventus Inc:

  • The EOD is -5.736. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -7.531. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is 6.855. Based on how much money comes from the company's main activities, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD-5.736MRQ-7.531+1.794
MRQ-7.531TTM6.855-14.386
TTM6.855YOY-1.288+8.143
TTM6.8555Y7.531-0.675
5Y7.53110Y5.793+1.738
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
EOD-5.736-2.842-2.894
MRQ-7.531-3.183-4.348
TTM6.855-1.612+8.467
YOY-1.288-3.401+2.113
3Y8.688-2.458+11.146
5Y7.531-3.239+10.770
10Y5.793-3.398+9.191
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Bioventus is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Medical Devices industry mean).
  • A PB ratio of 3.27 means the investor is paying $3.27 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Bioventus Inc:

  • The EOD is 2.494. Based on the equity, the company is underpriced. +1
  • The MRQ is 3.274. Based on the equity, the company is fair priced.
  • The TTM is 3.322. Based on the equity, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD2.494MRQ3.274-0.780
MRQ3.274TTM3.322-0.049
TTM3.322YOY1.239+2.083
TTM3.3225Y1.937+1.385
5Y1.93710Y1.490+0.447
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
EOD2.4942.030+0.464
MRQ3.2741.966+1.308
TTM3.3222.162+1.160
YOY1.2392.656-1.417
3Y1.7622.683-0.921
5Y1.9373.822-1.885
10Y1.4904.189-2.699
4.6.2. Total Gains per Share

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Bioventus Inc.

4.8.1. Institutions holding Bioventus Inc

Institutions are holding 71.55% of the shares of Bioventus Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2025-03-31Essex Woodlands Health Ventures19.62334.36791302132400
2025-03-31Juniper Investment Co, LLC10.457528.5519693935700
2025-03-31Nantahala Capital Management, LLC6.21731.54125650988412.4546
2025-03-31BlackRock Inc4.26560.00052830522375731.3453
2025-03-31Vanguard Group Inc3.84920.00042554224921433.7425
2025-03-31Divisadero Street Capital Management, LP2.551.5583169214916921490
2025-03-31Driehaus Capital Management LLC2.1780.1275144525732540229.0575
2025-03-31American Century Companies Inc1.57360.0059104421215953918.0337
2025-03-31FMR Inc1.50450.0006998349293993.0341
2025-03-31Geode Capital Management, LLC1.40570.0007932766-7110-0.7565
2025-03-31State Street Corp1.36930.0003908643-78552-7.9571
2025-03-31Royce & Associates, LP1.34460.088589221615998021.8481
2024-12-31Nuveen Asset Management, LLC1.17870.002378213713523620.9052
2025-03-31Oberweis Asset Management Inc0.90680.274460171400
2025-03-31Renaissance Technologies Corp0.83410.007755350016480042.3977
2025-03-31Dimensional Fund Advisors, Inc.0.78630.00125217379431522.066
2025-03-31Nuveen, LLC0.7740.00655136245136240
2025-03-31Morgan Stanley - Brokerage Accounts0.74310.0003493118-149484-23.2623
2025-03-31Charles Schwab Investment Management Inc0.67550.0008448247129032.9639
2025-03-31Northern Trust Corp0.57270.0005380017341019.8582
Total 62.809566.496241678763+3314859+8.0%

4.9.2. Funds holding Bioventus Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2025-05-31Vanguard Total Stock Mkt Idx Inv1.55440.0004103147400
2025-05-31iShares Russell 2000 ETF1.44920.010196165900
2025-05-31Avantis US Small Cap Value ETF1.36720.038590721614620.1614
2025-05-31Vanguard Institutional Extnd Mkt Idx Tr0.99460.003966002564500.9869
2025-03-31Oberweis Micro-Cap0.90680.92760171400
2025-03-31Oberweis Micro-Cap Growth0.90680.926160171400
2025-04-30Heptagon Driehaus US Micro Cap Eq C$ Acc0.85340.5601566327-7759-1.3515
2025-03-31Fidelity Small Cap Growth0.7540.06850034600
2025-03-31Royce Small-Cap Opportunity Invmt0.70970.44094709298069220.6777
2025-05-31FTGF RY US SmCp Opp A USD Dis(A)0.69050.3623458172398289.5204
2025-03-31Fidelity Small Cap Index0.57660.014538262047501.257
2025-05-31Invesco Dorsey Wright SmallCap Momt ETF0.35660.23823666000
2025-03-31Driehaus Micro Cap Growth USD0.35220.71292337018556257.7579
2025-03-31Driehaus Micro Cap Growth USD0.35220.7132337018654858.815
2025-05-31iShares Russell 2000 Value ETF0.34350.013822795500
2025-04-30Fidelity Extended Market Index0.33990.0046225565-2156-0.9468
2025-05-31State St Russell Sm/Mid Cp® Indx SL Cl I0.33790.003522425243001.955
2025-05-30Fidelity Enhanced Small Cap ETF0.32020.077421244700
2025-03-31Fidelity Small Cap Growth K60.31070.056920615400
2025-05-31Vanguard Russell 2000 ETF0.29320.0119457316960.8793
Total 13.76965.18199137204+301373+3.3%

5.3. Insider Transactions

Insiders are holding 11.866% of the shares of Bioventus Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2025-04-11Anthony D'adamioSELL29587.57
2025-04-11Mark Leonard SingletonSELL38757.57
2025-03-24Mark Leonard SingletonSELL54799.79
2025-03-17Katrina J ChurchSELL10189.75
2025-02-18Anthony D'adamioSELL438010.19
2025-02-18Mark Leonard SingletonSELL649810.19
2025-01-13Robert E ClaypooleSELL287869.1
2024-12-23Katrina J ChurchSELL253510.53
2024-12-23Mark Leonard SingletonSELL1073310.53
2024-08-19John A BartholdsonBUY255008.55
2024-08-16John A BartholdsonBUY800008.55
3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Latest Balance Sheet

Balance Sheet of 2025-03-31. Currency in USD. All numbers in thousands.

Summary
Total Assets691,414
Total Liabilities505,935
Total Stockholder Equity148,144
 As reported
Total Liabilities 505,935
Total Stockholder Equity+ 148,144
Total Assets = 691,414

Assets

Total Assets691,414
Total Current Assets249,367
Long-term Assets442,047
Total Current Assets
Cash And Cash Equivalents 22,802
Net Receivables 118,082
Inventory 94,045
Other Current Assets 14,438
Total Current Assets  (as reported)249,367
Total Current Assets  (calculated)249,367
+/-0
Long-term Assets
Property Plant Equipment 32,353
Goodwill 7,462
Intangible Assets 395,731
Long-term Assets Other 1,756
Long-term Assets  (as reported)442,047
Long-term Assets  (calculated)437,302
+/- 4,745

Liabilities & Shareholders' Equity

Total Current Liabilities174,751
Long-term Liabilities331,184
Total Stockholder Equity148,144
Total Current Liabilities
Short-term Debt 37,339
Short Long Term Debt 37,339
Accounts payable 19,197
Other Current Liabilities 112,080
Total Current Liabilities  (as reported)174,751
Total Current Liabilities  (calculated)205,955
+/- 31,204
Long-term Liabilities
Long term Debt 308,593
Long-term Liabilities Other 21,984
Long-term Liabilities  (as reported)331,184
Long-term Liabilities  (calculated)330,577
+/- 607
Total Stockholder Equity
Common Stock82
Retained Earnings -360,298
Accumulated Other Comprehensive Income -2,062
Other Stockholders Equity 510,422
Total Stockholder Equity (as reported)148,144
Total Stockholder Equity (calculated)148,144
+/-0
Other
Capital Stock82
Cash and Short Term Investments 22,802
Common Stock Shares Outstanding 66,009
Liabilities and Stockholders Equity 691,414
Net Debt 323,130
Net Invested Capital 494,076
Net Working Capital 74,616
Property Plant and Equipment Gross 32,353
Short Long Term Debt Total 345,932



5.2. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2025-03-312024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312016-03-312015-03-31
> Total Assets 
0
486,264
0
0
0
472,407
509,416
509,416
479,277
494,466
643,075
646,636
654,790
1,225,862
1,197,137
1,208,776
1,398,022
1,372,649
887,404
836,962
811,104
810,910
794,238
792,173
769,492
727,956
691,414
691,414727,956769,492792,173794,238810,910811,104836,962887,4041,372,6491,398,0221,208,7761,197,1371,225,862654,790646,636643,075494,466479,277509,416509,416472,407000486,2640
   > Total Current Assets 
0
99,985
0
0
0
64,520
234,410
234,410
193,141
211,794
270,721
290,060
246,078
263,103
245,395
277,157
271,082
272,575
308,664
260,638
249,452
267,999
265,903
308,883
298,688
275,610
249,367
249,367275,610298,688308,883265,903267,999249,452260,638308,664272,575271,082277,157245,395263,103246,078290,060270,721211,794193,141234,410234,41064,52000099,9850
       Cash And Cash Equivalents 
0
6,166
0
0
0
-64,520
126,240
126,240
72,478
86,839
124,247
136,065
80,917
43,933
27,374
41,001
34,359
31,814
47,102
29,389
26,827
36,964
25,173
31,994
43,074
41,582
22,802
22,80241,58243,07431,99425,17336,96426,82729,38947,10231,81434,35941,00127,37443,93380,917136,065124,24786,83972,478126,240126,240-64,5200006,1660
       Short-term Investments 
0
0
0
0
0
129,040
129,040
0
0
19,382
19,382
19,483
0
0
0
0
0
15
0
0
0
0
0
0
0
0
0
000000000150000019,48319,38219,38200129,040129,04000000
       Net Receivables 
0
51,109
0
0
0
85,128
67,352
67,352
80,813
88,283
89,472
102,029
105,442
124,963
119,288
143,018
132,185
136,912
118,544
119,636
112,899
123,046
125,541
137,305
121,925
127,393
118,082
118,082127,393121,925137,305125,541123,046112,899119,636118,544136,912132,185143,018119,288124,963105,442102,02989,47288,28380,81367,35267,35285,12800051,1090
       Other Current Assets 
0
5,591
0
0
0
6,059
7,062
7,062
5,145
7,552
17,194
17,946
46,308
32,519
34,042
48,120
27,586
18,418
55,065
15,337
12,163
16,656
18,184
51,978
43,657
14,160
14,438
14,43814,16043,65751,97818,18416,65612,16315,33755,06518,41827,58648,12034,04232,51946,30817,94617,1947,5525,1457,0627,0626,0590005,5910
   > Long-term Assets 
0
386,279
0
0
0
-64,520
275,006
275,006
286,136
282,672
372,354
356,576
408,712
962,759
951,742
931,619
1,126,940
1,100,074
578,740
576,324
561,652
542,911
528,335
483,290
470,804
452,346
442,047
442,047452,346470,804483,290528,335542,911561,652576,324578,7401,100,0741,126,940931,619951,742962,759408,712356,576372,354282,672286,136275,006275,006-64,520000386,2790
       Property Plant Equipment 
0
8,984
0
0
0
19,756
18,856
18,856
19,792
21,840
26,144
26,629
27,235
40,171
43,594
43,454
42,947
44,955
52,619
57,100
54,002
49,958
46,994
42,304
39,204
33,518
32,353
32,35333,51839,20442,30446,99449,95854,00257,10052,61944,95542,94743,45443,59440,17127,23526,62926,14421,84019,79218,85618,85619,7560008,9840
       Goodwill 
0
58,694
0
0
0
49,800
49,800
49,800
49,800
49,800
53,529
52,135
52,885
147,623
147,968
143,156
15,359
13,759
7,462
7,462
7,462
7,462
7,462
7,462
7,462
7,462
7,462
7,4627,4627,4627,4627,4627,4627,4627,4627,46213,75915,359143,156147,968147,62352,88552,13553,52949,80049,80049,80049,80049,80000058,6940
       Long Term Investments 
0
0
0
0
0
0
0
0
19,856
19,382
21,158
19,483
29,317
29,291
28,811
78,486
13,033
2,636
2,620
0
0
0
0
0
0
0
0
000000002,6202,63613,03378,48628,81129,29129,31719,48321,15819,38219,85600000000
       Intangible Assets 
0
318,141
0
0
0
216,510
202,938
202,938
196,688
191,650
271,042
257,848
248,794
695,193
681,369
666,523
1,055,601
1,038,724
516,039
505,223
493,324
482,350
470,668
424,552
414,809
404,729
395,731
395,731404,729414,809424,552470,668482,350493,324505,223516,0391,038,7241,055,601666,523681,369695,193248,794257,848271,042191,650196,688202,938202,938216,510000318,1410
       Other Assets 
0
0
0
0
0
0
0
0
0
34,343
481
481
50,481
50,481
50,000
0
0
0
0
0
0
0
0
0
0
0
0
00000000000050,00050,48150,48148148134,343000000000
> Total Liabilities 
0
299,962
0
0
0
326,790
367,625
367,625
333,938
350,306
422,793
427,272
424,293
692,073
675,219
688,586
1,018,876
1,032,317
647,042
603,621
584,648
589,792
576,806
603,111
582,659
542,352
505,935
505,935542,352582,659603,111576,806589,792584,648603,621647,0421,032,3171,018,876688,586675,219692,073424,293427,272422,793350,306333,938367,625367,625326,790000299,9620
   > Total Current Liabilities 
0
86,799
0
0
0
89,015
97,213
97,213
111,734
122,589
149,027
158,186
160,705
180,859
171,522
198,873
288,373
304,017
196,063
179,104
160,843
175,497
173,321
231,463
211,492
210,398
174,751
174,751210,398211,492231,463173,321175,497160,843179,104196,063304,017288,373198,873171,522180,859160,705158,186149,027122,589111,73497,21397,21389,01500086,7990
       Short-term Debt 
0
39,290
0
0
0
10,000
16,817
16,817
16,250
15,000
15,000
17,918
17,956
21,542
24,164
26,326
31,302
33,056
41,320
11,320
19,584
27,848
35,811
38,566
38,566
27,339
37,339
37,33927,33938,56638,56635,81127,84819,58411,32041,32033,05631,30226,32624,16421,54217,95617,91815,00015,00016,25016,81716,81710,00000039,2900
       Short Long Term Debt 
0
0
0
0
0
0
0
0
16,250
15,000
15,000
15,000
15,000
18,038
20,292
22,547
31,302
33,056
41,320
11,320
19,584
27,848
35,811
38,566
38,566
27,339
37,339
37,33927,33938,56638,56635,81127,84819,58411,32041,32033,05631,30222,54720,29218,03815,00015,00015,00015,00016,25000000000
       Accounts payable 
0
9,819
0
0
0
6,440
13,550
13,550
8,790
4,422
10,283
9,881
10,897
16,915
22,500
25,735
19,075
34,977
32,828
41,364
17,637
23,038
19,099
24,437
16,849
23,690
19,197
19,19723,69016,84924,43719,09923,03817,63741,36432,82834,97719,07525,73522,50016,91510,8979,88110,2834,4228,79013,55013,5506,4400009,8190
       Other Current Liabilities 
0
34,371
0
0
0
70,020
66,846
66,846
84,186
100,733
121,087
128,002
131,831
134,263
109,122
120,108
237,996
233,412
117,419
121,245
118,933
119,862
113,394
163,577
149,930
155,501
112,080
112,080155,501149,930163,577113,394119,862118,933121,245117,419233,412237,996120,108109,122134,263131,831128,002121,087100,73384,18666,84666,84670,02000034,3710
   > Long-term Liabilities 
0
213,163
0
0
0
237,775
270,412
270,412
222,204
227,717
273,766
269,086
263,588
511,214
503,697
489,713
730,503
728,300
450,979
424,517
423,805
414,295
403,485
371,648
371,167
331,954
331,184
331,184331,954371,167371,648403,485414,295423,805424,517450,979728,300730,503489,713503,697511,214263,588269,086273,766227,717222,204270,412270,412237,775000213,1630
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
166,084
162,437
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000162,437166,08400000000000
       Other Liabilities 
0
0
0
0
0
35,297
0
0
31,996
40,231
87,633
103,002
101,151
171,570
139,443
138,280
380,380
0
46,714
37,460
0
0
0
0
0
0
0
000000037,46046,7140380,380138,280139,443171,570101,151103,00287,63340,23131,9960035,29700000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
48,410
47,687
133,518
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000133,51847,68748,41000000000000
> Total Stockholder Equity
0
186,302
0
0
0
145,617
139,179
139,179
143,219
144,160
142,390
141,557
152,503
458,924
449,776
447,981
343,397
316,581
188,511
183,195
177,529
173,591
171,276
150,935
148,738
147,940
148,144
148,144147,940148,738150,935171,276173,591177,529183,195188,511316,581343,397447,981449,776458,924152,503141,557142,390144,160143,219139,179139,179145,617000186,3020
   Common Stock
0
284,837
0
0
0
285,147
285,135
285,135
285,173
285,173
57
57
57
75
78
80
80
78
79
79
79
79
80
81
81
82
82
8282818180797979797880807875575757285,173285,173285,135285,135285,147000284,8370
   Retained Earnings Total Equity0000000-308,137-304,4560-133,376-25,131-17,879-6,602-6,238-5,167-1,0410000000000
   Accumulated Other Comprehensive Income 
0
-560
0
0
0
-25,018
-721
-721
222
1,607
451
468
204
179
-363
-764
-1,340
-110
413
655
397
794
325
-17
445
-2,573
-2,062
-2,062-2,573445-17325794397655413-110-1,340-764-3631792044684511,607222-721-721-25,018000-5600
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
142,923
146,199
158,480
465,272
467,940
473,796
478,033
0
492,475
490,598
0
0
0
0
0
0
0
0000000490,598492,4750478,033473,796467,940465,272158,480146,199142,9230000000000
   Treasury Stock000000000000000000000000000
   Other Stockholders Equity 
0
284,837
0
0
0
2,635
2,635
0
2,342
1,919
142,923
146,199
158,480
465,272
467,940
473,796
478,033
481,919
492,475
490,598
492,493
494,254
496,977
500,969
503,134
505,509
510,422
510,422505,509503,134500,969496,977494,254492,493490,598492,475481,919478,033473,796467,940465,272158,480146,199142,9231,9192,34202,6352,635000284,8370



5.3. Balance Sheets

Currency in USD. All numbers in thousands.




5.4. Cash Flows

Currency in USD. All numbers in thousands.




5.5. Income Statements

Currency in USD. All numbers in thousands.


5.6. Latest Income Statement

Income Statement (annual), 2024-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue573,280
Cost of Revenue-185,054
Gross Profit388,226388,226
 
Operating Income (+$)
Gross Profit388,226
Operating Expense-400,205
Operating Income-11,979-11,979
 
Operating Expense (+$)
Research Development13,639
Selling General Administrative340,894
Selling And Marketing Expenses0
Operating Expense400,205354,533
 
Net Interest Income (+$)
Interest Income0
Interest Expense-38,792
Other Finance Cost-0
Net Interest Income-38,792
 
Pretax Income (+$)
Operating Income-11,979
Net Interest Income-38,792
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-49,12625,168
EBIT - interestExpense = -137,902
-38,835
5,250
Interest Expense38,792
Earnings Before Interest and Taxes (EBIT)-99,110-10,334
Earnings Before Interest and Taxes (EBITDA)-49,555
 
After tax Income (+$)
Income Before Tax-49,126
Tax Provision--5,293
Net Income From Continuing Ops-43,833-43,833
Net Income-33,542
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses585,259
Total Other Income/Expenses Net-37,14738,792
 

Technical Analysis of Bioventus
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Bioventus. The general trend of Bioventus is BEARISH with 42.9% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Bioventus's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-42.9%) Bearish trend (42.9%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Bioventus Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Bioventus Inc.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 8.43 < 9.56 < 10.13.

The bearish price targets are: 7.045 > 6.34 > 6.3341.

Know someone who trades $BVS? Share this with them.👇

Bioventus Inc Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Bioventus Inc. The current mas is .

The long score for the Moving Averages is 4/14.
The longshort score for the Moving Averages is -6/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Bioventus Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Bioventus Inc. The current macd is 0.10414136.

The long score for the Moving Average Convergence/Divergence (MACD) is 3/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 2/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Bioventus price going up in the near term. +2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Bioventus. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Bioventus price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Bioventus Inc Daily Moving Average Convergence/Divergence (MACD) ChartBioventus Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Bioventus Inc. The current adx is 18.26.

The long score for the Directional Movement Index (DMI) is 1/7.
The longshort score for the Directional Movement Index (DMI) is 1/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Bioventus shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
Bioventus Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Bioventus Inc. The current sar is 6.64619705.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Bioventus Inc Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Bioventus Inc. The current rsi is 52.37. The current phase is Correction in bear market.

The long score for the Relative Strength Index (RSI) is 3/13.
The longshort score for the Relative Strength Index (RSI) is 2/(-13 +13).

  • Correction in bear market: Extended price decline in a downtrend, significant pullback. Consider reducing exposure, wait for signs of trend reversal.
  • Trending down: The RSI is trending down. -1
Bioventus Inc Daily Relative Strength Index (RSI) ChartBioventus Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Bioventus Inc. The current phase is Correction in bear market.

The long score for the Stochastic Oscillator is 1/6.
The longshort score for the Stochastic Oscillator is -2/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Bioventus price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Bioventus Inc Daily Stochastic Oscillator ChartBioventus Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Bioventus Inc. The current cci is 85.95.

Bioventus Inc Daily Commodity Channel Index (CCI) ChartBioventus Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Bioventus Inc. The current cmo is 4.21248935.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Bioventus Inc Daily Chande Momentum Oscillator (CMO) ChartBioventus Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Bioventus Inc. The current willr is -38.52459016.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Bioventus is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Bioventus Inc Daily Williams %R ChartBioventus Inc Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Bioventus Inc.

Bioventus Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Bioventus Inc. The current atr is 0.32808896.

Bioventus Inc Daily Average True Range (ATR) ChartBioventus Inc Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Bioventus Inc. The current obv is 20,690,373.

Bioventus Inc Daily On-Balance Volume (OBV) ChartBioventus Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Bioventus Inc. The current mfi is 66.05.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Bioventus Inc Daily Money Flow Index (MFI) ChartBioventus Inc Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Bioventus Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2025-02-19WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-02-20CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-02-21STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-27STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-02-28STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-03SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2025-03-06SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-10STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-11DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-03-12MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-13MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-03-17STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-18STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-19MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-03-20STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-03-24STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-25MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-26CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-03-27SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-03-28WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-03-31STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-02CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-04-03STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-04-04CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-04-07STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-08STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-04-09RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-10STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-04-14STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-16STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-17STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-21STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-04-23SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-24MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-04-28STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-04-29STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-30SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-05-02STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-05STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-05-06MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-05-07RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-09STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-13CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-05-15MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-20SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-05-21STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-05-23STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-27STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-29STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-30STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-02WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-06-03STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-04STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-06STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-06-10CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-06-11STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-13CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-06-17SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-06-20STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-23CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-06-24CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-06-25SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-06-26STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-27STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-30STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-07-01DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-07-03WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-07-07STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-08STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-07-09BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-07-11STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).

6.3. Candlestick Patterns

Bioventus Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Bioventus Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5052.374
Ma 20Greater thanMa 506.785
Ma 50Greater thanMa 1006.731
Ma 100Greater thanMa 2007.892
OpenGreater thanClose7.320
Total3/5 (60.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Bioventus with someone you think should read this too:
  • Are you bullish or bearish on Bioventus? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Bioventus? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Bioventus Inc

I send you an email if I find something interesting about Bioventus Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Bioventus Inc.

Receive notifications about Bioventus Inc in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.